RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Polymyositis: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
3.69P Clinicopathological characteristics of polymyositis with mitochondrial pathology (PM-Mito)
Shogo Komaki et al., Neuromuscular Disorders (29 September 2026)
https://doi.org/10.1016/j.nmd.2026.107091
- 2.
3.82P Proteomic characterization of COX-SDH abnormal fibres in polymyositis with mitochondrial pathology
Karsten Krause et al., Neuromuscular Disorders (29 September 2026)
https://doi.org/10.1016/j.nmd.2026.107104
- 3.
3.94P Reclaim-PM: a retrospective reclassification of muscle biopsies diagnosed as polymyositis using contemporary clinico-sero-pathological criteria
Julian Sehne et al., Neuromuscular Disorders (29 September 2026)
https://doi.org/10.1016/j.nmd.2026.107116
- 4.
Clinical features and prognostic factors of hospitalized patients with acute exacerbation of interstitial lung disease secondary to dermatomyositis/polymyositis.
Ba Cuirong et al., Clinical rheumatology (22 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42771104/
- 5.
Causal link between polymyositis and idiopathic pulmonary fibrosis in individuals of European ancestry: A Mendelian randomization and multi-omics study identifying mediators and drug targets.
Chen Miaomiao et al., Medicine (21 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42629724/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449 · Recruiting · Phase 3 · AstraZeneca
Ages 18 to 75
https://clinicaltrials.gov/study/NCT06455449
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Polymyositis
Polymyositis is a rare autoimmune disease in which the immune system attacks muscle fibres, causing inflammation and weakness, mainly in the muscles closest to the trunk such as the hips, thighs and shoulders. It usually develops over weeks to months in adults. Treatment generally involves corticosteroids and other immune-suppressing medicines, along with physiotherapy.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Polymyositis?
Polymyositis is a rare autoimmune disease in which the immune system attacks muscle fibres, causing inflammation and weakness, mainly in the muscles closest to the trunk such as the hips, thighs and shoulders. It usually develops over weeks to months in adults. Treatment generally involves corticosteroids and other immune-suppressing medicines, along with physiotherapy.
How many clinical trials are available for Polymyositis?
RareWays currently indexes 44 clinical trials for Polymyositis, of which 7 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Polymyositis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Polymyositis.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.